ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin, quantity: 50 mg/ml - oral liquid, powder for - excipient ingredients: sodium lauryl sulfate; allura red ac; methylcellulose; dimeticone 350; xanthan gum; pregelatinised maize starch; sucrose; flavour - indications as at 24 february 2004: keflex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. keflex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of keflex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of keflex in the treatment of bacterial infections of the brain and spinal column has not been established and keflex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to keflex. renal function studies should be performed when indicated.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin, quantity: 25 mg/ml - oral liquid, powder for - excipient ingredients: sodium lauryl sulfate; allura red ac; methylcellulose; dimeticone 350; xanthan gum; pregelatinised maize starch; sucrose; flavour - indications as at 24 february 2004: keflex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. keflex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of keflex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of keflex in the treatment of bacterial infections of the brain and spinal column has not been established and keflex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to keflex. renal function studies should be performed when indicated.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - oxycodone hydrochloride, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: saccharin sodium; sodium citrate dihydrate; sodium benzoate; hypromellose; sodium hydroxide; hydrochloric acid; purified water; citric acid monohydrate - oxynorm is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - clavulanic acid, quantity: 11.4 mg/ml; amoxicillin, quantity: 80 mg/ml - oral liquid, powder for - excipient ingredients: silicon dioxide; succinic acid; colloidal anhydrous silica; aspartame; xanthan gum; hypromellose; flavour - augmentin duo 400 oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology). skin and skin structure infections: urinary tract infections (complicated and uncomplicated): upper respiratory tract infections including sinusitis, otitis media: lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin. however, when there is good reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptible studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin duo 400, should not require the addition of another antibiotic due to the amoxycillin content of augmentin duo 400.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - prednisolone sodium phosphate, quantity: 6.72 mg/ml (equivalent: prednisolone, qty 5 mg/ml) - oral liquid, solution - excipient ingredients: disodium edetate; dibasic sodium phosphate; propyl hydroxybenzoate; sorbitol solution (70 per cent) (non-crystallising); methyl hydroxybenzoate; purified water; monobasic sodium phosphate; flavour - wherever corticosteroid therapy is indicated.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 26.86 mg/ml (equivalent: cefaclor, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; tapioca starch; erythrosine; sucrose; flavour - ceclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ceclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of ceclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 53.72 mg/ml (equivalent: cefaclor, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; tapioca starch; erythrosine; sucrose; flavour - ceclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ceclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of ceclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - paracetamol, quantity: 48 mg/ml - oral liquid, solution - excipient ingredients: benzoic acid; hydrochloric acid; purified water; potassium sorbate; allura red ac; glycerol; macrogol 1500; propylene glycol; saccharin sodium; sorbitol solution (70 per cent) (non-crystallising); flavour - for the relief of pain and fever.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lactulose solution, quantity: 1 ml/ml (equivalent: lactulose, qty 660 mg/ml) - oral liquid, solution - excipient ingredients: - for the treatment of acute, and the prevention and treatment of chronic portal-systemic encephalopathy, including the stages of hepatic precoma and coma. for the treatment of chronic and habitual constipation.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenytoin, quantity: 6 mg/ml - oral liquid, suspension - excipient ingredients: sodium benzoate; polysorbate 40; citric acid monohydrate; glycerol; purified water; carmellose sodium; ethanol; vanillin; carmoisine; sucrose; sunset yellow fcf; aluminium magnesium silicate; flavour - dilantin is indicated for the control of grand mal and psychomotor seizures. dilantin will prevent or effectively decrease the incidence and severity of convulsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. besides its effectiveness in controlling seizures, dilantin frequently improves the mental condition and outlook of epileptic patients and there is also increasing evidence that dilantin is valuable in the prevention of seizures occurring during or after neurosurgery and in the treatment of certain cardiac arrythmias. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administration).